Drug-related adverse events were all of mild intensity and reported in seven participants : one in the @ g idarucizumab group ( infusion site erythema and hot flushes ) , one in the @ g plus @ g idarucizumab group ( epistaxis ) ; one receiving placebo ( infusion site haematoma ) , and four during dabigatran etexilate pretreatment ( three haematuria and one epistaxis ) .